CELLULOSE ANTIGEN RECEPTORS SHOW SPECIFICITY TO B CELL ADULT ANTIGENS AND THEY CONTAIN PHARMACEUTICALS
VN10062260BActive Publication Date: 2026-11-02REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- VN1202402431
- Authority / Receiving Office
- VN · VN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-07-18
- Publication Date
- 2026-11-02
- Estimated Expiration
- 2039-07-18
Abstract
The invention relates to B-cell mature antigen (BCMA) expressed on malignant plasma cells. The invention relates to BCMA-specific mosaic antigen receptors and cells expressing these mosaic antigen receptors. By the defined scheme, engineered cells expressing the mosaic antigen receptors in this invention are capable of inhibiting the growth of BCMA-expressing tumors. The engineered cells in this invention are useful in the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desirable and / or therapeutically beneficial. For example, the engineered cells expressing BCMA-specific mosaic antigen receptors in this invention are useful in the treatment of various cancers, including multiple myeloma.
Need to check novelty before this filing date? Find Prior Art
